Epstein Files Full PDF

CLICK HERE
Technopedia Center
PMB University Brochure
Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education
teknopedia

  • Registerasi
  • Brosur UTI
  • Kip Scholarship Information
  • Performance
Flag Counter
  1. World Encyclopedia
  2. Cephamycin - Wikipedia
Cephamycin - Wikipedia
From Wikipedia, the free encyclopedia
Group of β-lactam antibiotics
Core structure of the cephamycins.

Cephamycins are a group of β-lactam antibiotics. They are very similar to cephalosporins, and the cephamycins are sometimes classified as cephalosporins.

Like cephalosporins, cephamycins are based upon the cephem nucleus. Unlike most cephalosporins, cephamycins are a very efficient antibiotic against anaerobic microbes.[citation needed]

Cephamycins were originally produced by Streptomyces, but synthetic ones have been produced as well.[citation needed]

Cephamycins possess a methoxy group at the 7-alpha position.[1]

In addition, cephamycins have been shown to be stable against extended-spectrum beta-lactamase (ESBL) producing organisms, although their use in clinical practice is lacking for this indication.[2]

Examples

[edit]

Cephamycins include:

  • Cefoxitin[3]
  • Cefotetan[4]
  • Cefmetazole[5]

References

[edit]
  1. ^ Oreste A. Mascaretti (2003). Bacteria Versus Antibacterial Agents: An Integrated Approach. American Society Microbiology. p. 144. ISBN 1-55581-258-9.
  2. ^ Munoz-Price, L (2017). "Chapter 185: Antibiotic Resistance". Principles and Practice of Hospital Medicine (2nd ed.). New York: McGraw-Hill Education.
  3. ^ Little PJ, Peddie BA (July 1978). "Clinical use of cefoxitin, a new semisynthetic cephamycin". N. Z. Med. J. 88 (616): 46–9. PMID 279853.
  4. ^ Clarke AM, Zemcov SJ (January 1983). "Antibacterial activity of the cephamycin cefotetan: an in-vitro comparison with other beta-lactam antibiotics". J. Antimicrob. Chemother. 11. Suppl: 67–72. doi:10.1093/jac/11.suppl_A.67. PMID 6404881.
  5. ^ Benlloch M, Torres A, Soriano F (October 1982). "Cefmetazole (CS-1170): a new cephamycin with activity against gram-negative bacilli and staphylococci". J. Antimicrob. Chemother. 10 (4): 347–50. doi:10.1093/jac/10.4.347. PMID 6958672.
  • v
  • t
  • e
Antibacterials active on the cell wall and envelope (J01C-J01D)
β-lactams
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases
)
Penicillins (Penams)
Narrow
spectrum
β-lactamase sensitive
(1st generation)
  • Benzylpenicillin (G)#
  • Benzathine benzylpenicillin#
  • Procaine benzylpenicillin#
  • Phenoxymethylpenicillin (V)#
  • Propicillin‡
  • Pheneticillin‡
  • Azidocillin‡
  • Clometocillin‡
  • Penamecillin‡
β-lactamase resistant
(2nd generation)
  • Cloxacillin# (Dicloxacillin
  • Flucloxacillin)
  • Oxacillin
  • Nafcillin
  • Methicillin‡
Extended
spectrum
Aminopenicillins (3rd generation)
  • Amoxicillin#
  • Ampicillin# (Pivampicillin
  • Hetacillin‡
  • Bacampicillin‡
  • Lenampicillin
  • Metampicillin‡
  • Talampicillin‡)
  • Epicillin‡
Carboxypenicillins (4th generation)
  • Ticarcillin
  • Carbenicillin‡ / Carindacillin‡
  • Temocillin‡
Ureidopenicillins (4th generation)
  • Piperacillin
  • Azlocillin‡
  • Mezlocillin‡
Other
  • Mecillinam (Pivmecillinam)
  • Sulbenicillin‡
Carbapenems / Penems
  • Carbapenems (Ertapenem
  • Antipseudomonal (Doripenem
  • Imipenem
  • Meropenem)
  • Biapenem‡
  • Panipenem)
  • Penems (Faropenem
  • Ritipenem§
  • Sulopenem)
Cephems
Cephalosporins
Cephamycins
Carbacephems
1st generation
  • Cefazolin#
  • Cefalexin #
  • Cefadroxil
  • Cefapirin
  • Cefazedone‡
  • Cefazaflur‡
  • Cefradine‡
  • Cefroxadine‡
  • Ceftezole‡
  • Cefaloglycin‡
  • Cefacetrile‡
  • Cefalonium‡
  • Cefaloridine‡
  • Cefalotin
  • Cefatrizine‡
2nd generation
  • Cefaclor
  • Cefprozil
  • Cefuroxime
  • Cefuroxime axetil
  • Cefamandole‡
  • Cefonicid‡
  • Ceforanide‡
  • Cefuzonam‡
  • Cephamycin (Cefoxitin
  • Cefotetan
  • Cefminox‡
  • Cefbuperazone‡
  • Cefmetazole‡)
  • Carbacephem (Loracarbef‡)
3rd generation
  • Cefixime#
  • Ceftriaxone#
  • Cefotaxime#
  • Antipseudomonal (Ceftazidime#
  • Cefoperazone)
  • Cefdinir
  • Cefcapene
  • Cefdaloxime
  • Ceftizoxime
  • Cefmenoxime
  • Cefpiramide
  • Cefpodoxime
  • Ceftibuten
  • Cefditoren
  • Cefotiam‡
  • Cefetamet‡
  • Cefodizime‡
  • Cefpimizole‡
  • Cefsulodin‡
  • Cefteram‡
  • Ceftiolene‡
  • Oxacephem (Flomoxef
  • Latamoxef‡)
4th generation
  • Cefepime
  • Cefozopran‡
  • Cefpirome
  • Cefquinome‡
5th generation
  • Ceftaroline fosamil
  • Ceftolozane
  • Ceftobiprole
Siderophore
  • Cefiderocol#
Veterinary
  • Ceftiofur
  • Cefquinome
  • Cefovecin
Monobactams
  • Aztreonam
  • Tigemonam‡
  • Carumonam‡
  • Nocardicin A‡
β-lactamase inhibitors
  • Penam (Sulbactam
  • Tazobactam
  • Enmetazobactam)
  • Clavam (Clavulanic acid)
  • non-β-lactam (Avibactam
  • Durlobactam
  • Relebactam
  • Taniborbactam
  • Vaborbactam)
Combinations
  • Amoxicillin/clavulanic acid#
  • Ampicillin/flucloxacillin
  • Ampicillin/sulbactam (Sultamicillin)
  • Aztreonam/avibactam
  • Benzathine benzylpenicillin/procaine benzylpenicillin
  • Cefepime/enmetazobactam
  • Cefepime/sulbactam
  • Cefoperazone/sulbactam
  • Ceftazidime/avibactam
  • Ceftolozane/tazobactam
  • Imipenem/cilastatin#
  • Imipenem/cilastatin/relebactam
  • Meropenem/vaborbactam
  • Panipenem/betamipron
  • Piperacillin/tazobactam
  • Sulbactam/durlobactam
  • Sulopenem/probenecid
  • Ticarcillin/clavulanic acid
Polypeptides
Lipopeptides
  • Insert into bacterial cell wall causing perforation and depolarization: Daptomycin
  • Surfactin
Other
  • Inhibits PG elongation and crosslinking: Ramoplanin§
Intracellular
  • Inhibit PG subunit synthesis and transport: NAM synthesis inhibition
    • Fosfomycin
  • DADAL/AR inhibitors
    • Cycloserine
    • Terizidone
  • bactoprenol inhibitors
    • Bacitracin
Other
  • Hydrolyze NAM-NAG
    • Lysozyme
  • Tyrothricin
    • Gramicidin
    • Tyrocidine
  • Isoniazid#
  • Teixobactin
  • #WHO-EM
  • ‡Withdrawn from market
  • Clinical trials:
    • †Phase III
    • §Never to phase III


Stub icon

This systemic antibiotic-related article is a stub. You can help Wikipedia by adding missing information.

  • v
  • t
  • e
Retrieved from "https://teknopedia.ac.id/w/index.php?title=Cephamycin&oldid=1299491162"
Categories:
  • Cephalosporin antibiotics
  • Antibiotic stubs
Hidden categories:
  • CS1: long volume value
  • Articles with short description
  • Short description is different from Wikidata
  • All articles with unsourced statements
  • Articles with unsourced statements from January 2023
  • All stub articles

  • indonesia
  • Polski
  • العربية
  • Deutsch
  • English
  • Español
  • Français
  • Italiano
  • مصرى
  • Nederlands
  • 日本語
  • Português
  • Sinugboanong Binisaya
  • Svenska
  • Українська
  • Tiếng Việt
  • Winaray
  • 中文
  • Русский
Sunting pranala
url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url
Pusat Layanan

UNIVERSITAS TEKNOKRAT INDONESIA | ASEAN's Best Private University
Jl. ZA. Pagar Alam No.9 -11, Labuhan Ratu, Kec. Kedaton, Kota Bandar Lampung, Lampung 35132
Phone: (0721) 702022
Email: pmb@teknokrat.ac.id